Clinical Trial Update: Gemcitabine/Nab-Paclitaxel With HIGRT in Resectable Pancreatic Cancer [NA]

View source ↗

Summary

Clinical trial update for Gemcitabine/Nab-Paclitaxel with high-dose conformal radiotherapy (HIGRT) in resectable pancreatic cancer; study completed with results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Gemcitabine/Nab-Paclitaxel (gemcitabine; nab-paclitaxel)
• HIGRT (high-dose conformal radiotherapy)

Snippet

Sponsor: Duke University | Conditions: Resectable Pancreatic Cancers | NA | Status: COMPLETED | Results posted: 2021-07-01